Investment Management Corp of Ontario Buys 3,274 Shares of IDEXX Laboratories, Inc. $IDXX

Investment Management Corp of Ontario grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 52,069 shares of the company’s stock after acquiring an additional 3,274 shares during the quarter. Investment Management Corp of Ontario owned about 0.07% of IDEXX Laboratories worth $35,226,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. Gotham Asset Management LLC lifted its position in shares of IDEXX Laboratories by 22.8% during the 4th quarter. Gotham Asset Management LLC now owns 59,738 shares of the company’s stock valued at $40,415,000 after acquiring an additional 11,095 shares during the period. Evolve Private Wealth LLC bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $419,000. First Manhattan CO. LLC. lifted its position in shares of IDEXX Laboratories by 139.9% during the 4th quarter. First Manhattan CO. LLC. now owns 2,171 shares of the company’s stock valued at $1,469,000 after acquiring an additional 1,266 shares during the period. Capitolis Liquid Global Markets LLC bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $1,780,000. Finally, City National Bank of Florida MSD bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $203,000. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $546.09 on Thursday. IDEXX Laboratories, Inc. has a 12-month low of $506.91 and a 12-month high of $769.98. The business has a 50-day simple moving average of $562.51 and a two-hundred day simple moving average of $622.66. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The stock has a market cap of $43.08 billion, a PE ratio of 40.21, a PEG ratio of 3.13 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the prior year, the firm earned $2.91 EPS. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on IDXX shares. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. UBS Group lowered their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Stifel Nicolaus lowered their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Finally, Citigroup initiated coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target for the company. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.